Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma - PubMed (original) (raw)
Clinical Trial
. 2011 Apr 15;128(8):1981-8.
doi: 10.1002/ijc.25528.
Maja Bradic Lindh, Malin Jarvius, Marjut Puputti, Monica Nistér, Nina N Nupponen, Werner Paulus, Ola Söderberg, Gregor Dresemann, Andreas von Deimling, Heikki Joensuu, Arne Ostman, Martin Hasselblatt
Affiliations
- PMID: 20589679
- DOI: 10.1002/ijc.25528
Clinical Trial
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma
Janna Paulsson et al. Int J Cancer. 2011.
Abstract
Platelet-derived growth factor receptor (PDGFR) signaling has been implicated in the pathogenesis of glioblastomas and represents a target for the tyrosine kinase inhibitor imatinib. To examine the prognostic or predictive role of PDGFRs in recurrent glioblastomas, expression was examined in tumor samples of 101 patients of CSTI571BDE40, a randomized trial comparing hydroxyurea monotherapy and a combination of hydroxyurea and imatinib. Furthermore, PDGFRα phosphorylation was investigated using in situ proximity ligation assay. PDGFRα protein was expressed in 33% of tumors and was associated with male sex, young age, presence of R132H mutated isocitrate dehydrogenase 1 protein and short median survival (142 vs. 187 days, p = 0.028). Tumor PDGFRα phosphorylation was also associated with short survival (p = 0.030). The subset of patients with PDGFRα positive glioblastoma did not have longer survival on treatment with hydroxyurea and imatinib compared with hydroxyurea monotherapy. In conclusion, both PDGFRα protein expression and phosphorylation status had a prognostic role in recurrent glioblastomas but did not define a group that showed benefit from the combination therapy consisting of hydroxyurea and imatinib.
Copyright © 2010 UICC.
Similar articles
- Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA. Haberler C, et al. J Neurooncol. 2006 Jan;76(2):105-9. doi: 10.1007/s11060-005-4570-9. J Neurooncol. 2006. PMID: 16205964 - Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. J Clin Oncol. 2005 Dec 20;23(36):9359-68. doi: 10.1200/JCO.2005.03.2185. J Clin Oncol. 2005. PMID: 16361636 Clinical Trial. - Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
Dresemann G. Dresemann G. Ann Oncol. 2005 Oct;16(10):1702-8. doi: 10.1093/annonc/mdi317. Epub 2005 Jul 20. Ann Oncol. 2005. PMID: 16033874 Clinical Trial. - In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Fréneaux P, Livartowski A, Pouillart P, Poupon MF. Decaudin D, et al. Int J Cancer. 2005 Feb 20;113(5):849-56. doi: 10.1002/ijc.20652. Int J Cancer. 2005. PMID: 15499612 Review. - Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
Mathew P, Fidler IJ, Logothetis CJ. Mathew P, et al. Semin Oncol. 2004 Apr;31(2 Suppl 6):24-9. doi: 10.1053/j.seminoncol.2004.03.037. Semin Oncol. 2004. PMID: 15176001 Review.
Cited by
- The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens.
Mahajan S, Schmidt MHH, Schumann U. Mahajan S, et al. Cancers (Basel). 2023 Mar 28;15(7):2024. doi: 10.3390/cancers15072024. Cancers (Basel). 2023. PMID: 37046685 Free PMC article. Review. - Molecular targeted therapy: A new avenue in glioblastoma treatment.
El Atat O, Naser R, Abdelkhalek M, Habib RA, El Sibai M. El Atat O, et al. Oncol Lett. 2022 Dec 15;25(2):46. doi: 10.3892/ol.2022.13632. eCollection 2023 Feb. Oncol Lett. 2022. PMID: 36644133 Free PMC article. Review. - EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.
Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, Lan X, Zhang L, Miao JY, Wang YX, Zhu J, Yang FC, Lu HM, Yan ZX, Chen FL, Shi Y, Ping YF, Cui YH, Zhang X, Liu X, Yao XH, Lv SQ, Bian XW, Wang Y. Gai QJ, et al. Signal Transduct Target Ther. 2022 Feb 2;7(1):33. doi: 10.1038/s41392-021-00855-2. Signal Transduct Target Ther. 2022. PMID: 35105853 Free PMC article. - Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
Aldaz P, Arozarena I. Aldaz P, et al. Cancers (Basel). 2021 Nov 18;13(22):5799. doi: 10.3390/cancers13225799. Cancers (Basel). 2021. PMID: 34830952 Free PMC article. Review. - Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications.
Basheer AS, Abas F, Othman I, Naidu R. Basheer AS, et al. Cancers (Basel). 2021 Aug 23;13(16):4226. doi: 10.3390/cancers13164226. Cancers (Basel). 2021. PMID: 34439380 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous